Perspective Therapeutics Inc
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Perspective Therapeutics' stock with a target price of $13, indicating strong potential growth.
Financial Health
Perspective Therapeutics Inc has modest revenue and cash flow, indicating stable operations but limited growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CATX
Future Tech: World Changing Ideas
Get ahead of tomorrow's innovations with this collection of stocks pushing technological boundaries. Our analysts have carefully selected companies developing flying cars, breakthrough medical treatments, and robotic surgery that could reshape our future.
Published: May 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Catalysts to Watch
Clinical readouts, regulatory announcements and partnership deals can move the stock; such events may create opportunity but also add volatility.
Funding & Runway
Cash position and access to financing are crucial for early-stage healthcare firms; dilution is possible if new capital is required.
Research Sources
Use filings, investor presentations and regulator sites for verified updates; third-party commentary can help but check primary documents.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
